BTIG Research Reiterates Buy Rating for Kestra Medical Technologies (NASDAQ:KMTS)

Kestra Medical Technologies (NASDAQ:KMTS)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $32.00 price target on the stock. BTIG Research’s price target would indicate a potential upside of 62.60% from the company’s previous close.

Several other research firms have also recently commented on KMTS. Piper Sandler boosted their target price on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. The Goldman Sachs Group set a $24.00 price objective on shares of Kestra Medical Technologies in a report on Friday, January 16th. Stifel Nicolaus set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Wells Fargo & Company increased their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

Kestra Medical Technologies Price Performance

KMTS stock opened at $19.68 on Wednesday. The stock has a 50-day moving average price of $23.74 and a two-hundred day moving average price of $24.61. Kestra Medical Technologies has a 1 year low of $13.25 and a 1 year high of $30.00. The stock has a market cap of $1.15 billion and a PE ratio of -4.97. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The firm had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm’s revenue was up 62.7% compared to the same quarter last year.

Insider Buying and Selling

In other news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the sale, the insider owned 364,786 shares of the company’s stock, valued at approximately $7,394,212.22. This represents a 3.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Traci S. Umberger sold 10,500 shares of the firm’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the completion of the transaction, the insider directly owned 136,633 shares of the company’s stock, valued at $3,646,734.77. This represents a 7.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 70,500 shares of company stock valued at $1,709,145. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

A number of large investors have recently added to or reduced their stakes in KMTS. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter worth about $31,000. Russell Investments Group Ltd. lifted its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Kestra Medical Technologies during the third quarter worth about $48,000. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies during the fourth quarter worth about $72,000. Finally, BNP Paribas Financial Markets increased its position in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.